Accounting for Cured Patients in Cost-Effectiveness Analysis

Berkson, 1952, Survival curve for cancer patients following treatment, J Am Stat Assoc, 47, 501, 10.1080/01621459.1952.10501187 Kuk, 1992, A mixture model combining logistic regression with proportional hazards regression, Biometrika, 79, 531, 10.1093/biomet/79.3.531 Peng, 2000, A nonparametric mixture model for cure rate estimation, Biometrics, 56, 237, 10.1111/j.0006-341X.2000.00237.x Sy, 2000, Estimation in a Cox proportional hazards cure model, Biometrics, 56, 227, 10.1111/j.0006-341X.2000.00227.x Yin, 2005, Cure rate models: a unified approach, Can J Stat, 33, 559, 10.1002/cjs.5550330407 Lambert, 2007, Estimating and modeling the cure fraction in population-based cancer survival analysis, Biostatistics, 8, 576, 10.1093/biostatistics/kxl030 Lambert, 2007, Modeling of the cure fraction in survival studies, Stata J, 7, 1, 10.1177/1536867X0700700304 Etzioni, 1999, On the use of survival analysis techniques to estimate medical care costs, J Health Econ, 18, 365, 10.1016/S0167-6296(98)00056-3 Lin, 1997, Estimating medical costs from incomplete follow-up data, Biometrics, 53, 419, 10.2307/2533947 Hodi, 2010, Improved survival with ipilimumab in patients with metastatic melanoma, N Engl J Med, 363, 711, 10.1056/NEJMoa1003466 Davies, 2012, The ends justify the mean: outcome measures for estimating the value of new cancer therapies, Health Outcomes Res Med, 3, e25, 10.1016/j.ehrm.2012.01.001 Ederer, 1961, The relative survival rate: a statistical methodology, Natl Cancer Inst Monogr, 6, 101 Tromme, 2014, Health-related quality of life in patients with melanoma expressed as utilities and disability weights, Br J Dermatol, 171, 1443, 10.1111/bjd.13262 Seidler, 2010, Economic burden of melanoma in the elderly population: population-based analysis of the Surveillance, Epidemiology, and End Results (SEER)–Medicare data, Arch Dermatol, 146, 249, 10.1001/archdermatol.2009.389 Culver, 2011, Ipilimumab: a novel treatment for metastatic melanoma, Ann Pharmacother, 45, 510, 10.1345/aph.1P651 2015 Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma | 1-guidance | Guidance and guidelines | NICE. http://www.nice.org.uk/guidance/ta268/chapter/1-guidance.